16. (Amended) A transgenic organism according to claim 13, wherein the prothrombin or prothrombin-related polypeptide comprises a region having the amino acid sequence of human thrombin.

Q3

17. (Amended) A transgenic organism according to claim 1, where in the prothrombin or prothrombin related polypeptide comprises a region having an amino acid sequence 80% to 100% identical to that of a mammalian prothrombin.

Q4

20. (Amended) A transgenic organism according to claim 17, wherein the prothrombin or prothrombin-related polypeptide comprises a region having the amino acid sequence of human prothrombin.

Q5

29. (Amended) A prothrombin or prothrombin-related polypeptide isolated from a transgenic organism according to claim 28 that differs in its post-translational modification from naturally occurring prothrombin polypeptides.

Q6

31. (Amended) A prothrombin or prothrombin-related polypeptide according to claim 28 having a specific activity is 75% to 125% of that of purified human prothrombin.

Q7

35. (Amended) A prothrombin or prothrombin-related polypeptide according to claim 33, wherein the prothrombin or prothrombin-related polypeptide comprises a region having the amino acid sequence of human thrombin.

Q8

38. (Amended) A prothrombin or prothrombin-related polypeptide according to claim 36, wherein the prothrombin or prothrombin-related polypeptide comprises a region having the amino acid sequence of human prothrombin.

Q9 43. (Amended) A composition according to claim 40, wherein the prothrombin or prothrombin-related polypeptide has a specific activity 75% to 125% of that of purified human prothrombin.

Q10 46. (Amended) A composition according to claim 44, wherein the prothrombin or prothrombin-related polypeptide comprises a region having the amino acid sequence of human thrombin.

Q11 48. (Amended) A composition according to claim 46, wherein the prothrombin or prothrombin-related polypeptide comprises a region having the amino acid sequence of human prothrombin.

Q12 53. (Amended) A method for treating a wound in a patient comprising a step of administering to said patient a composition according to claim 40.